Go Back

Limited supply of Remdesivir for COVID-19 patients

07 Jun 2020

If your patients may benefit, consult pulmonology

By: Danielle Britt, PharmD

Oregon Health Authority acquired a limited amount of Remdesivir for Oregon to treat patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19. Remdesivir is available for use in eligible, hospitalized patients at Salem Hospital.

Patients must meet FDA EUA criteria and receive written informed consent prior to administration of Remdesivir. Remdesivir is only dispensed through the state on an individual patient basis. Hospitals may not stockpile the drug and any vials that are not used, must be returned to the state within 48 hours. Hospitalized patients located on any floor of the hospital may receive Remdesivir but a pulmonary consult is required for ordering. Specific inclusion and exclusion criteria is located on the Salem Health intranet page here:

Note: Pregnant and pediatric patients are not eligible for state supply and must apply for compassionate use directly through Gilead.

If you feel that your patient would benefit from Remdesivir therapy, consult pulmonology to review the patient. Preliminary data shows that it is best to administer the drug when the hospitalized patient is on supplemental oxygen, not improving, and prior to progressing to intubation. If the patient is eligible, the pulmonologist will contact pharmacy to see if a course of Remdesivir is obtainable. Typically, Remdesivir is available same day if ordered by 12 p.m. or the next day if ordered after 12 p.m. Weekend or holiday requests may be delayed. Once the state’s supply of Remdesivir has been exhausted, notification will be sent out to providers and the Salem Health COVID-19 treatment guideline will be updated.

Additional helpful links or contact information:

Our resource people:

Danielle Britt, MA, PharmD AMS/ ID Pharmacist

Jasmin Chaudhary, MD AMS/ Infection Prevention Medical Director

Gwen (Sierra) Schneider, DVM, RN, BNS, CCRN, ICU coordinator